*My main point is that to me (not an expert in a life science), GENR's descriptions of Evizon's MOA do not seem "murky", particularly not murky "in spades".*
I agree. The MOA of Evizon is NOT murky at all. This is another 'agenda' driven statement by an individual who makes comparisons to a drug whose molecular ID and MOA is completely and unadulteratedly DIFFERENT in every way, shape and form. It does not warrant/justify a scientific comparison. I find the science of Evizon's "nature derived" treatment for AMD to be nothing short of a miracle! Let's talk about the murky characteristics GTCB's science instead of what is clear and straight forward in slide 38 on GENR's website. The fact is that Evizon is working better than any other drug to treat AMD and is demonstrating no more toxicity than a placebo. Let me also point out that April 1st has now come and gone WITHOUT a pipe, although I must say I thought Dew's prediction was going to be correct. Unfortunately, I thought the same thing when I purchased a large amount of GTCB at much higher levels before dumping in the mid $1's, thank God.---biocrio
Market Data 
Markets 
AI
